Now Playing
|Videos|August 5, 2022
Where Will Tumor-Infiltrating Lymphocyte (TIL) Therapy Fit Into the Oncologic Landscape?
Author(s)Allison Betof Warner, MD, PhD
In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental therapies may fit in the oncologic landscape.
Advertisement
Episodes in this series
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5